Supplementation with all three macular carotenoids provides greatest benefits for AMD patients

Supplementation with all three macular carotenoids provides greatest benefits for AMD patients

Supplementation with all three macular carotenoids administered in a precise ratio confers greatest visual improvements

By John Nolan PhD, Prof. Stephen Beatty

Take-home message: The AREDS2 findings have empowered ophthalmologists to recommend appropriate supplements to reduce risk of visual loss in patients with AMD. In this article, the authors discuss the emerging revelation that the constituents of macular pigment enhance visual performance and explain how supplementation with all three macular carotenoids in a MZ:L:Z (mg) ratio of 10:10:2 can confer the greatest benefits.

 We live in an ageing society, the importance of which is compounded by the fact that people are having smaller families. Consequently, and inevitably, the elderly section of the population is becoming an ever-increasing proportion of the overall population. Indeed, it has been estimated that the 65 year and older section of the Irish population (for the purpose of this report, we are using the Republic of Ireland [RoI] as a case study) will account for 15% of the Irish population by 2011; and 19% by 2031, from a stable baseline of 11% for the last 40 years (Irish Department of Health, 1999).1 Of note, the greatest increases in numbers will be seen amongst the very old (for example, the number of people aged over 80 years of age is expected to increase by 66% by 2035).

The impact of AMD

Age-related macular degeneration is the leading cause of blind registration in the western world.Epidemiological studies carried out in different countries have been remarkably consistent, and all have demonstrated that the amount of vision loss and eye disease increases dramatically with increasing age.3,4 For each decade over the age of 40 years, the amount of blindness and vision loss increases three-fold. Interestingly, 48% of all cases of blind registration in persons aged 40 years and over is attributable to AMD. AMD is seen in about 2% of the 70 to 80 year old age group, 4% in the 81 to 84 (incl.) year old age group and 13% in those aged 85 years and older. As the aging of society is an unprecedented phenomenon it is unsurprising that AMD accounted for only a tiny proportion of blindness at the beginning of the 20th century……….

Read more:http://ophthalmologytimes.modernmedicine.com/node/411070

Source: Ophthalmology Times

Image : Ophthalmology Times